Lexicon Pharmaceuticals (LXRX) Q4 Loss Narrows to $0.04 Per Share Despite 79% Revenue Plunge to $5.5M

Loss narrows sharply. Lexicon Pharmaceuticals reported a Q4 2025 loss of $0.04 per share, narrower than the year-ago loss of  $0.09 per share, marking a 55.56% improvement year-over-year. Revenue came in at $5.5 million for the quarter. The company posted a net loss of $15.5 million, with an operating loss of $14.8 million against gross profit of $5.3 million and cost of revenue of $201 million. Shares traded flat at $1.61 on volume of 2.4 million shares, within the day’s range of $1.57 to $1.66.

Revenue collapses year-over-year. The $5.5 million in quarterly revenue represents a dramatic 79.31% decline from the year-ago period. The biotechnology company’s gross margin remained strong at 96.3%, with cost of revenue representing just $201 million. The company held its earnings call at 8:30 AM ET on March 5, 2026, with both the press release and webcast replay available through its investor relations portal.